Coronavirus Disease 2019 Assosiated Pneumonia in China: Current Status and Future Prospects

Abstract

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) linked with coronavirus disease 2019 (COVID-19) poses a serious threat to public health worldwide. Firstly, the SARS-CoV-2 was reported in Wuhan, Hubei Province, China in December 2019. Initially, the major proportion of virus-infected cases (i.e. about 99%) was reported in China and now it is being reported in other counties as well. Humans begin to be infected within their communities and transmittance of the viral epidemic increased rapidly due to lack of understanding of its transmission routes and precautionary measures. The existence of SARS-CoV-2 in China threatened the population greatly due to the high incidence of fatal respiratory infections. Current investigations speculated that this virus transferred into a human from viral-infected bats. However, the process of interspecies viral transmission is an important scientific question to be addressed. Due to the continuous increase in the patients infected with COVID-19 associated pneumonia, the World Health Organization (WHO) has included this viral epidemic to the priority list of diseases. Therefore, accelerated research developments are required to control the spread of this outbreak, as it is declared as a public health emergency by WHO especially in the absence of efficacious drugs and vaccines. Our review encompasses the recent status of disease severity in China, a particular replication mechanism of SARS-CoV-2 and potential risks and precautionary measures required to avoid contact with this fatal viral infection.

Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro

“…COVID-19 has quickly turned into a global pandemic, affected millions of people, and claimed tens of thousands of human lives worldwide. Currently, there is no approved drug or vaccine to combat COVID-19 (Ahmed et al, 2020;Tahir ul Qamar, Rehman, et al, 2020). Several antiviral drugs are in clinical trials and only remdesivir appeared to be the most promising (Cao et al, 2020) which is being tested in patients with severe disease (Cao et al, 2020;Hillaker et al, 2020).…”

Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches

“…Coronaviruses (CoVs) are enveloped RNA viruses covered with a non-segmented positive-sense RNA genome of 28 to 30 kb, known since the mid-1960s [ 1 ]. These viruses can infect a variety of hosts and can cause different respiratory, enteric, liver, and systemic diseases [ 1 , 2 ]. CoVs have the potential to transmit among animals and humans [ 3 , 4 ], that is evident from previous CoVs outbreaks.…”

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics andin silicoapproaches

“…Symptoms such as fever, diarrhea and respiratory disorder are present in infected people 4 . According to the recent research SARS-CoV-2 has an identical genomic organization as of beta-coronaviruses, 5’-untranslated region (UTR) includes orf1ab (replicas complex), nsps (encoding non-structural proteins), S (spike protein) and 3’-UTR includes E-protein (envelope protein), M-protein (membrane protein), Oraf6, orf7a, orf8, N-protein (nucleocapsid protein), orf10, and a lot of unknown non-structural open reading frames 3, 8 .…”